2.50
Hdl Handle:
http://hdl.handle.net/10033/15855
Title:
Vaccines against typhoid fever.
Authors:
Guzman, Carlos A; Borsutzky, Stefan; Griot-Wenk, Monika; Metcalfe, Ian C; Pearman, Jon; Collioud, Andre; Favre, Didier; Dietrich, Guido
Abstract:
Because of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.
Affiliation:
Vaccine Research Group, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, Braunschweig, Germany.
Citation:
Vaccines against typhoid fever. 2006, 24 (18):3804-11 Vaccine
Journal:
Vaccine
Issue Date:
1-May-2006
URI:
http://hdl.handle.net/10033/15855
DOI:
10.1016/j.vaccine.2005.07.111
PubMed ID:
16278037
Type:
Article
Language:
en
ISSN:
0264-410X
Appears in Collections:
publications of the research group vaccinology and applied microbiology (VAC)

Full metadata record

DC FieldValue Language
dc.contributor.authorGuzman, Carlos A-
dc.contributor.authorBorsutzky, Stefan-
dc.contributor.authorGriot-Wenk, Monika-
dc.contributor.authorMetcalfe, Ian C-
dc.contributor.authorPearman, Jon-
dc.contributor.authorCollioud, Andre-
dc.contributor.authorFavre, Didier-
dc.contributor.authorDietrich, Guido-
dc.date.accessioned2008-01-09T10:03:02Z-
dc.date.available2008-01-09T10:03:02Z-
dc.date.issued2006-05-01-
dc.identifier.citationVaccines against typhoid fever. 2006, 24 (18):3804-11 Vaccineen
dc.identifier.issn0264-410X-
dc.identifier.pmid16278037-
dc.identifier.doi10.1016/j.vaccine.2005.07.111-
dc.identifier.urihttp://hdl.handle.net/10033/15855-
dc.description.abstractBecause of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.en
dc.language.isoenen
dc.subject.meshAntigens, Bacterialen
dc.subject.meshCross Reactionsen
dc.subject.meshHumansen
dc.subject.meshParatyphoid Feveren
dc.subject.meshPolysaccharides, Bacterialen
dc.subject.meshSalmonella paratyphi Aen
dc.subject.meshSalmonella typhien
dc.subject.meshTyphoid Feveren
dc.subject.meshTyphoid-Paratyphoid Vaccinesen
dc.subject.meshVaccines, Attenuateden
dc.subject.meshVaccines, Inactivateden
dc.subject.meshVaccines, Subuniten
dc.titleVaccines against typhoid fever.en
dc.typeArticleen
dc.contributor.departmentVaccine Research Group, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, Braunschweig, Germany.en
dc.identifier.journalVaccineen
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.